Dysregulation of brain reward systems in obesity: measuring endogenous dopamine levels by acute dopamine depletio

Conditions: fatty degeneration
obesity
10003018

Registration Number: NL-OMON34239

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

* Female;
* Age 18-45 years;
* BMI >35 of 18-25 kg/m2;
* Caucasian;
* Able to provide written informed consent and to comply with all study procedures.

Exclusion Criteria

* Currently dependent on any substance including nicotine or cannabis;
* Diabetes mellitus and/or dyslipidemia;
* Hypertension necessitating more than one type of medication;
* Severe neurological or psychiatric disorders (e.g., depression, psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications);
* Serious medical illnesses;
* Drugs known to influence binding to D2R, including neuroleptics, and methylphenidate;
* Clinically significant abnormal laboratory values;
* Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication;
* Pregnancy or breastfeeding;
* Contraindications for MRI scan (claustrofobia, inclusion of metal components in the body, e.g. pacemaker)
* Measurements crossing maximum weight and size criteria for MRI and SPECT scanner.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Availability of dopamine D2 receptors (D2R) in the striatum before and after<br /><br>dopamine depletion (difference is baseline dopamine level)<br /><br>- eating behavior<br /><br>- correlations between baseline dopamine level, striatal D2R availability,<br /><br>eating behavior, and BMI</p><br>

Secondary Outcome Measures